Clinical trial · no report yet · Phase 2
NEOVADE
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
- NCT06300424 ↗
- Active not recruiting
- Guangdong Provincial People's Hospital
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Non Small Cell Lung Cancer; EGFR Gene Mutation
- Interventions
- almonertinib; Carboplatin; Nab paclitaxel
- Arms
- Almonertinib and Chemo-immunotherapy · Experimental
- Enrollment
- 32 (estimated)
- Primary outcomes
- Major Pathological Response (MPR)
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 1, 2024
- Primary completion
- Jan 26, 2026
- Results posted
- No
- Registry record
- NCT06300424 · updated Apr 29, 2026